Pelvic exenteration for vulvar cancer: contemporary outcomes from a multinational cohort study
European Journal of Surgical Oncology · 2026
DOI: 10.1016/j.ejso.2026.111468 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Surgical Oncology, 2026. Verfasst von Diana Zach und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women's and Children's Health, Karolinska Institutet, and Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Swede…. Hauptthemen laut MEDLINE: Pelvic Exenteration, Vulvar Neoplasms, Postoperative Complications, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Women with vulvar cancer are considerably older than those with other gynaecological malignancies, raising concerns about the tolerability of radical surgery. Yet, for locally advanced or recurrent disease, pelvic exenteration may be the only curative option. Robust evidence to guide decision-making in this population is lacking. MATERIAL AND METHODS: This multicentre observational cohort study used data from the COREPEX registry including women who underwent anterior or total pelvic exenteration between 2005 and 2023 across 20 European tertiary referral centres. The primary outcome was overall survival (OS); secondary outcomes were progression-free survival (PFS) and major postoperative complications. Associations were assessed using multivariable Cox and binomial regression models adjusted for relevant covariates. RESULTS: Among 861 women, 79 (9.2%) had vulvar cancer. Median follow-up was 49 months for OS and 40 months for PFS. Women with vulvar cancer were older and more often overweight. Five-year OS was 32% (95% CI, 19-46) in vulvar cancer versus 29% (95% CI, 25-34) in other cancers, adjusted HR 1.05 (95% CI, 0.75-1.46). Five-year PFS was 34% versus 29%, adjusted HR 0.96 (95% CI, 0.69-1.34). Major complications occurred in 33% vs 29%, adjusted RR 1.12 (95% CI, 0.77-1.58). Lymph node metastases, positive margins, and recurrent or persistent disease independently predicted poorer survival. CONCLUSION: Despite their older age, women with vulvar cancer had survival and morbidity comparable to those with other gynaecological malignancies. These findings support pelvic exenteration as a curative option for selected women with vulvar cancer when complete resection is feasible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Women's and Children's Health, Karolinska Institutet, and Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden. Electronic address: diana.zach@ki.se.
- UOC Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- Division of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
- Department of Surgical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
- First Obstetrics and Gynaecology Clinic, "G. E. Palade" University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania.
- Department of Gynecologic Oncology, La Fe University and Polytechnic Hospital, Valencia, Spain; POG Department, University of Valencia, Valencia, Spain.
Zitieren
APA
Zach, D., Querleu, D., Ul Hassan, M., Loverro, M., Ricotta, G., Cãpîlna, M. E., Domingo, S., Cibula, D., Novák, Z., Miranda, A., Chacon, E., Zapardiel, I., Svintsitskyi, V., Matylevich, O., van Ramshorst, G. H., Taskiran, C., Demirkıran, F., Vizzielli, G., Fanfani, F., …, & Salehi, S. (2026). Pelvic exenteration for vulvar cancer: contemporary outcomes from a multinational cohort study. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2026.111468
Vancouver
Zach D, Querleu D, Ul Hassan M, Loverro M, Ricotta G, Cãpîlna ME, et al. Pelvic exenteration for vulvar cancer: contemporary outcomes from a multinational cohort study. European Journal of Surgical Oncology. 2026. doi:10.1016/j.ejso.2026.111468
BibTeX
@article{Zach2026,
author = {Zach, Diana and Querleu, Denis and Ul Hassan, Mahmood and Loverro, Matteo and Ricotta, Giulio and Cãpîlna, Mihai Emil and Domingo, Santiago and Cibula, David and Novák, Zoltan and Miranda, Andrea and Chacon, Enrique and Zapardiel, Ignacio and Svintsitskyi, Valentyn and Matylevich, Olga and van Ramshorst, Gabrielle H and Taskiran, Cagatay and Demirkıran, Fuat and Vizzielli, Giuseppe and Fanfani, Francesco and Garganese, Giorgia and Fagotti, Anna and Martinez, Alejandra and Gauroy, Elodie and Cucinella, Giuseppe and Muallem, Mustafa Zelal and Bizzarri, Nicolò and Salehi, Sahar},
title = {Pelvic exenteration for vulvar cancer: contemporary outcomes from a multinational cohort study},
journal = {European Journal of Surgical Oncology},
year = {2026},
doi = {10.1016/j.ejso.2026.111468}
}
EUVIMED